Eisai Co. Ltd.
www.eisai.com
Latest From Eisai Co. Ltd.
Immuno-Oncology Continues To Draw Pharma Companies To The Deal Table
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
GemVax's Novel Peptide For Alzheimer’s Set To Advance After Positive Phase II
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gastrointestinal
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Inflammation
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Eisai Co. Ltd.
- Senior Management
-
Haruo Naito, Pres. & CEO
Ryohei Yanagi, CFO
Edward Stewart Geary, CMO - Contact Info
-
Eisai Co. Ltd.
Phone: (81) 3 3817 3700
4-6-10 Koishikawa
Bunkyo-ku
Tokyo, 112-8088
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice